A major IPO can be expected to attract a lot of new attention (and capital) to the psychedelic drug industry.
Psychedelics
Novamind Appoints Dr. Reid Robison as Chief Medical Officer
Novamind Ventures' new CMO has led over 100 clinical trials and currently serves as a Coordinating Investigator for MAPS.
Psychedelic Drugs Go Mainstream
As the Renaissance for psychedelic drugs progresses, we see these substances acquiring mainstream status in various ways.
Champignon to Begin Offering Esketamine Treatment for Adults With Major Depressive Disorder at the Canadian Rapid Treatment Centre of Excellence
Champignon Brands advises that the BCSC has revoked its original cease trade order (June 19, 2020), but a replacement order remains in effect.
Mydecine Innovations Group Announces Extended Lock-Up Arrangement
Certain large Mydecine shareholders have entered into a voluntary lock-up, covering 52,908,420 common shares.
MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD
MindMed is utilizing MDMA with LSD, to endeavour to reduce side effects of LSD-assisted therapy.
Why Are Silicon Valley AND Wall Street Backing Psychedelic Drugs?
Wall Street and Silicon Valley investors recently piled into a $30-million psychedelics fund-raising initiative.
Field Trip Psychedelics Inc. Announces Closing of $11.0 million Financing, Entry into Amalgamation Agreement with Newton Energy Corporation
Field Trip Psychedelics completes its qualifying transaction and definitive agreement with RTO partner.
Wuhan General Group Corporate Update
Wuhan General (soon to be M2Bio Sciences) has released a corporate update on its psychedelics and cannabis operations.
IntelGenx Enters into Feasibility Agreement with ATAI Life Sciences to Develop Pharmaceutical-Grade Polymeric Film-Based Psychedelics
IntelGenX enters into agreement with ATAI Life Sciences to develop novel formulations of pharmaceutical-grade psychedelics.
ATAI Life Sciences Forges Premier Psychedelics R&D Platform
ATAI Life Sciences is preparing to add three new drug development partners as it builds the premier R&D platform in the psychedelics space.
PSYC Establishes New Partnership with Industry Leader, Microdose Psychedelic Insights
Global Trac Solutions is developing a media partnership with Microdose.
Psychedelic Drugs: Powerful Medicine, Life-Changing Results
Psychedelic drug therapies continue to win over new supporters. But the clock is ticking with our Mental Health Crisis...
Mydecine™ Launches World's First Natural-Sourced cGMP Psilocybin for Global Research, Sales, and Distribution Enterprise
Mydecine is ready to start supplying GMP-quality psilocybin to advance psychedelics R&D.
Field Trip Psychedelics Inc. Expands Stateside With Psychedelic-Enhanced Psychotherapy Clinic in New York City
Field Trip adds a ketamine-assisted psychotherapy clinic to its operations.